https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-phase-1b-trial-data BiopharmaWatch en 2026-10-11T20:00:00.000Z First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/IART/integra-announces-pricing-senior-secured-notes BiopharmaWatch en 2026-10-09T21:22:00.000Z Integra Announces Pricing of Senior Secured Notes https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-closes-registered-direct-offering BiopharmaWatch en 2026-10-09T20:32:00.000Z Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-nasdaq-notification-minimum-bid-price BiopharmaWatch en 2026-10-09T20:30:00.000Z CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026